Algorae Pharmaceuticals Limited has released a press release.
LCT Interim CEO Appointed
Filed with ASX ·
6ix hasn’t read this filing yet.
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- LCT exits peptide projects
- LCT CEO Dr Ken Taylor signals intention to retire
- Preliminary Final Report and 2020 Financial Statements
- Amended Appendix 4C
- Response to ASX Aware Query
Later from Algorae Pharmaceuticals
- Preliminary Final Report and 2021 Financial Statements
- Secures Funds for 3rd Trial of NTCELL in Parkinson Disease
- LCT Signs MOU with NZeno, Secures Pig Cells for NTCELL Trial
- LCT Advises Price Change for Rights Issue
- LCT Receives New Zealand R&D Tax Credit
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals